397 related articles for article (PubMed ID: 29868026)
1. Coming of Age: CD96 Emerges as Modulator of Immune Responses.
Georgiev H; Ravens I; Papadogianni G; Bernhardt G
Front Immunol; 2018; 9():1072. PubMed ID: 29868026
[TBL] [Abstract][Full Text] [Related]
2. Altered expression of CD226 and CD96 on natural killer cells in patients with pancreatic cancer.
Peng YP; Xi CH; Zhu Y; Yin LD; Wei JS; Zhang JJ; Liu XC; Guo S; Fu Y; Miao Y
Oncotarget; 2016 Oct; 7(41):66586-66594. PubMed ID: 27626490
[TBL] [Abstract][Full Text] [Related]
3. Human CD96 Correlates to Natural Killer Cell Exhaustion and Predicts the Prognosis of Human Hepatocellular Carcinoma.
Sun H; Huang Q; Huang M; Wen H; Lin R; Zheng M; Qu K; Li K; Wei H; Xiao W; Sun R; Tian Z; Sun C
Hepatology; 2019 Jul; 70(1):168-183. PubMed ID: 30411378
[TBL] [Abstract][Full Text] [Related]
4. The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions.
Chan CJ; Martinet L; Gilfillan S; Souza-Fonseca-Guimaraes F; Chow MT; Town L; Ritchie DS; Colonna M; Andrews DM; Smyth MJ
Nat Immunol; 2014 May; 15(5):431-8. PubMed ID: 24658051
[TBL] [Abstract][Full Text] [Related]
5. Interaction between nectin-1 and the human natural killer cell receptor CD96.
Holmes VM; Maluquer de Motes C; Richards PT; Roldan J; Bhargava AK; Orange JS; Krummenacher C
PLoS One; 2019; 14(2):e0212443. PubMed ID: 30759143
[TBL] [Abstract][Full Text] [Related]
6. Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy.
Blake SJ; Stannard K; Liu J; Allen S; Yong MC; Mittal D; Aguilera AR; Miles JJ; Lutzky VP; de Andrade LF; Martinet L; Colonna M; Takeda K; Kühnel F; Gurlevik E; Bernhardt G; Teng MW; Smyth MJ
Cancer Discov; 2016 Apr; 6(4):446-59. PubMed ID: 26787820
[TBL] [Abstract][Full Text] [Related]
7. Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy.
Blake SJ; Dougall WC; Miles JJ; Teng MW; Smyth MJ
Clin Cancer Res; 2016 Nov; 22(21):5183-5188. PubMed ID: 27620276
[TBL] [Abstract][Full Text] [Related]
8. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.
Dougall WC; Kurtulus S; Smyth MJ; Anderson AC
Immunol Rev; 2017 Mar; 276(1):112-120. PubMed ID: 28258695
[TBL] [Abstract][Full Text] [Related]
9. CD96 interaction with CD155 via its first Ig-like domain is modulated by alternative splicing or mutations in distal Ig-like domains.
Meyer D; Seth S; Albrecht J; Maier MK; du Pasquier L; Ravens I; Dreyer L; Burger R; Gramatzki M; Schwinzer R; Kremmer E; Foerster R; Bernhardt G
J Biol Chem; 2009 Jan; 284(4):2235-44. PubMed ID: 19056733
[TBL] [Abstract][Full Text] [Related]
10. CD96 functions as a co-stimulatory receptor to enhance CD8
Chiang EY; de Almeida PE; de Almeida Nagata DE; Bowles KH; Du X; Chitre AS; Banta KL; Kwon Y; McKenzie B; Mittman S; Cubas R; Anderson KR; Warming S; Grogan JL
Eur J Immunol; 2020 Jun; 50(6):891-902. PubMed ID: 32043568
[TBL] [Abstract][Full Text] [Related]
11. CD155 immunoregulation as a target for natural killer cell immunotherapy in glioblastoma.
Lupo KB; Matosevic S
J Hematol Oncol; 2020 Jun; 13(1):76. PubMed ID: 32532329
[TBL] [Abstract][Full Text] [Related]
12. [CD226, TIGIT and CD96 regulate NK cell function and participate in anti-tumor immunity].
Zhang H; Liu R; Zhang Y; Liu X; Chen L
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2023 Sep; 39(9):852-856. PubMed ID: 37732582
[TBL] [Abstract][Full Text] [Related]
13. Suppression of Natural Killer cell NKG2D and CD226 anti-tumour cascades by platelet cloaked cancer cells: Implications for the metastatic cascade.
Cluxton CD; Spillane C; O'Toole SA; Sheils O; Gardiner CM; O'Leary JJ
PLoS One; 2019; 14(3):e0211538. PubMed ID: 30908480
[TBL] [Abstract][Full Text] [Related]
14. CD155, an onco-immunologic molecule in human tumors.
Gao J; Zheng Q; Xin N; Wang W; Zhao C
Cancer Sci; 2017 Oct; 108(10):1934-1938. PubMed ID: 28730595
[TBL] [Abstract][Full Text] [Related]
15. CD96 targeted antibodies need not block CD96-CD155 interactions to promote NK cell anti-metastatic activity.
Roman Aguilera A; Lutzky VP; Mittal D; Li XY; Stannard K; Takeda K; Bernhardt G; Teng MWL; Dougall WC; Smyth MJ
Oncoimmunology; 2018; 7(5):e1424677. PubMed ID: 29721390
[TBL] [Abstract][Full Text] [Related]
16. Structural Basis for CD96 Immune Receptor Recognition of Nectin-like Protein-5, CD155.
Deuss FA; Watson GM; Fu Z; Rossjohn J; Berry R
Structure; 2019 Feb; 27(2):219-228.e3. PubMed ID: 30528596
[TBL] [Abstract][Full Text] [Related]
17. Hitting the complexity of the TIGIT-CD96-CD112R-CD226 axis for next-generation cancer immunotherapy.
Jin HS; Park Y
BMB Rep; 2021 Jan; 54(1):2-11. PubMed ID: 33298247
[TBL] [Abstract][Full Text] [Related]
18. Tumor-derived soluble CD155 inhibits DNAM-1-mediated antitumor activity of natural killer cells.
Okumura G; Iguchi-Manaka A; Murata R; Yamashita-Kanemaru Y; Shibuya A; Shibuya K
J Exp Med; 2020 Mar; 217(4):1. PubMed ID: 32040157
[TBL] [Abstract][Full Text] [Related]
19. CD96 as a Potential Immune Regulator in Cancers.
Feng S; Isayev O; Werner J; Bazhin AV
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674817
[TBL] [Abstract][Full Text] [Related]
20. Functional characterization of DNAM-1 (CD226) interaction with its ligands PVR (CD155) and nectin-2 (PRR-2/CD112).
Tahara-Hanaoka S; Shibuya K; Onoda Y; Zhang H; Yamazaki S; Miyamoto A; Honda S; Lanier LL; Shibuya A
Int Immunol; 2004 Apr; 16(4):533-8. PubMed ID: 15039383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
